Clicky

Greenwich LifeSciences, Inc.(GLSI)

Description: Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.


Keywords: Medicine Biopharmaceutical Clinical Medicine Surgery Immunotherapy Breast Cancer Cancer Treatment Clinical Trial Acid Treatment Of Breast Cancer Her2/Neu Her2 Cancer Center

Home Page: greenwichlifesciences.com

GLSI Technical Analysis

Building 14
Stafford, TX 77477
United States
Phone: 832 819 3232


Officers

Name Title
Mr. Snehal S. Patel CEO, CFO & Director
Mr. Eric Rothe Founder & Independent Director
Dr. Frank Joseph Daugherty M.D. Chief Medical Officer & Director
Dr. Jaye L. Thompson Ph.D. VP of Clinical & Regulatory Affairs
Dr. Christine T. Fischette Ph.D. VP of Bus. Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 10.9471
Price-to-Sales TTM: 0
IPO Date: 2020-09-25
Fiscal Year End: December
Full Time Employees: 3
Back to stocks